高级检索
当前位置: 首页 > 详情页

Sagittal abdominal diameter and Framingham risk score in non-dialysis chronic kidney disease patients

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Division of Nephrology, The First Affiliated Hospitalof Kunming Medical University, 295 Xichang Road,Kunming 650032, Yunnan province, China [2]Division of Nephrology, The Second Affiliated Hospitalof Kunming Medical University, Kunming, Yunnan Province,China [3]Division of Nephrology, Puer People’s Hospital, Puer,Yunnan Province, China [4]Intensive Care Unit, General Hospital of Ningxia MedicalUniversity, Yinchuan, China [5]Department of Nephrology, The First People’s Hospitalof Xuzhou, Xuzhou, Jiangsu Province, China [6]Division of Nephrology, Peking University Third Hospital,Beijing, China
出处:
ISSN:

关键词: Central obesity CVD Anthropometry Body weight

摘要:
Background Chronic kidney disease (CKD) is very common now and is associated with high overall and cardiovascular mortality. Numerous studies have reported that abdominal obesity is a risk factor for cardiovascular mortality. We investigated the link between sagittal abdominal diameter (SAD) and Framingham risk score in non-dialysis CKD patients. Methods In a cross-sectional study, we enrolled 307 prevalent non-dialysis CKD patients (175 males, aged 50.7 +/- 17.04 years). SAD and Framingham risk score were measured. Results Framingham cardiovascular disease risk score was independently predicted by SAD (P < 0.01), GFR (P < 0.01) and diabetic history (P < 0.05). Adjusted R-2 of the model was 0.178. SAD could be independently predicted by BMI (P < 0.01), diabetic history (P < 0.01), GFR (P < 0.01) and age (P < 0.01). Adjusted R-2 of the model was 0.409. Using receiver operating characteristic (ROC) curve, a cutoff SAD value of 16.55 cm was determined with sensitivity of 63.7%, specificity of 58.3%. Conclusion Elevated SAD is significantly associated with increased Framingham risk score in non-dialysis CKD patients. SAD can be predicted by patients' BMI, diabetic history, renal function and age. Further investigation is needed to explore the potential benefits of central obesity lowering therapy in this patient group.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
JCR分区:
出版当年[2018]版:
Q3 UROLOGY & NEPHROLOGY
最新[2023]版:
Q3 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Division of Nephrology, The First Affiliated Hospitalof Kunming Medical University, 295 Xichang Road,Kunming 650032, Yunnan province, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)